Company: WHWK
Filing Date: 2025-03-04
Form Type: 8-K
Source: 0001193125-25-045605
Chunk: 1

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-03-04
Form: 8-K
Item: Item 5.07
Chunk 1
---
───────────────────────────────────────────────────
  12,898,905      7,202,353            4,426                     0  

Proposal 3: The Equity Plan Increase Proposal

         For        Against      Abstentions      Broker Non-Votes  
 ────────────────────────────────────────────────────────────────────
  11,863,025      8,234,637            8,022                     0  

Proposal 4: The Golden Parachutes Proposal

         For        Against      Abstentions      Broker Non-Votes  
 ────────────────────────────────────────────────────────────────────
  15,490,810      4,598,457           16,417                     0  

Proposal 5: The Adjournment Proposal

         For        Against      Abstentions      Broker Non-Votes  
 ────────────────────────────────────────────────────────────────────
  15,121,060      4,948,986           35,638                     0  

Item 7.01 Regulation FD Disclosure.

On March 4, 2025, the Company issued a press release announcing the closing of the PIPE Financing. The press release is attached as Exhibit 99.1 to this report and incorporated into this Item 7.01 by reference.

The information in this Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act, except as expressly set forth by specific reference in such filing.